Clinical trial
A Phase I/II Study of Sunitinib and Dacarbazine
NCT00496223 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00496223 |
|---|---|
| Title | A Phase I/II Study of Sunitinib and Dacarbazine |
| Official title | A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Sunitinib, Dacarbazine |
| Enrollment | 11 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jul 4, 2007 |
| Last update posted | Feb 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: